Se-Jin Lee

List of Publications by Year
in descending order

40 papers	8,621 citations	186265 28 h-index	315739 38 g-index
40 all docs	40 docs citations	40 times ranked	9429 citing authors

#	Article	IF	Citations
1	Deletion of <i>Gdf15</i> Reduces ER Stress-induced Beta-cell Apoptosis and Diabetes. Endocrinology, 2022, 163, .	2.8	10
2	Functional replacement of myostatin with GDF-11 in the germline of mice. Skeletal Muscle, 2022, 12, 7.	4.2	6
3	Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. Journal of Clinical Investigation, 2021, 131, .	8.2	55
4	Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-Î² signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	5
5	Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30907-30917.	7.1	33
6	Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23942-23951.	7.1	71
7	Precise Spatiotemporal Control of Nodal Na+ Channel Clustering by Bone Morphogenetic Protein-1/Tolloid-like Proteinases. Neuron, 2020, 106, 806-815.e6.	8.1	9
8	GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4910-4920.	7.1	45
9	Cover Image, Volume 234, Number 12, December 2019. Journal of Cellular Physiology, 2019, 234, i.	4.1	0
10	Activin type II receptor signaling in cardiac aging and heart failure. Science Translational Medicine, 2019, 11, .	12.4	95
11	Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 65-84.	2.4	19
12	Bone morphogenetic protein 9 as a key regulator of liver progenitor cells in <scp>DDC</scp>â€induced cholestatic liver injury. Liver International, 2018, 38, 1664-1675.	3.9	26
13	Follistatin Targets Distinct Pathways To Promote Brown Adipocyte Characteristics in Brown and White Adipose Tissues. Endocrinology, 2017, 158, 1217-1230.	2.8	49
14	BMP-9 interferes with liver regeneration and promotes liver fibrosis. Gut, 2017, 66, 939-954.	12.1	107
15	Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. Journal of Cell Biology, 2017, 216, 149-165.	5.2	250
16	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntingtonâ€™s disease mice. Scientific Reports, 2017, 7, 14275.	3.3	27
17	Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass. Journal of Biological Chemistry, 2017, 292, 13809-13822.	3.4	50
18	Fibroblast-specific TGF-Î²â€“Smad2/3 signaling underlies cardiac fibrosis. Journal of Clinical Investigation, 2017, 127, 3770-3783.	8.2	603

#	Article	IF	Citations
19	Paracrine and endocrine modes of myostatin action. Journal of Applied Physiology, 2016, 120, 592-598.	2.5	30
20	TGFÎ²1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discovery, 2016, 6, 1366-1381.	9.4	196
21	BMP1-like proteinases are essential to the structure and wound healing of skin. Matrix Biology, 2016, 56, 114-131.	3.6	41
22	Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-Î² signaling. Oncotarget, 2016, 7, 84314-84325.	1.8	9
23	Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta. Bone Research, 2015, 3, 14042.	11.4	42
24	Genome-wide expression analysis comparing hypertrophic changes in normal and dysferlinopathy mice. Genomics Data, 2015, 6, 253-257.	1.3	0
25	Roles of GASP-1 and GDF-11 in Dental and Craniofacial Development. Journal of Oral Medicine and Pain, 2015, 40, 110-114.	0.2	8
26	Alternative Binding Modes Identified for Growth and Differentiation Factor-associated Serum Protein (GASP) Family Antagonism of Myostatin. Journal of Biological Chemistry, 2015, 290, 7506-7516.	3.4	35
27	Induced ablation of Bmp1 and Tll1 produces osteogenesis imperfecta in mice. Human Molecular Genetics, 2014, 23, 3085-3101.	2.9	58
28	Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2353-60.	7.1	156
29	Treating cancer cachexia to treat cancer. Skeletal Muscle, 2011, 1, 2.	4.2	44
30	Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2010, 10, 183-194.	0.5	92
31	Regulation of Muscle Mass by Follistatin and Activins. Molecular Endocrinology, 2010, 24, 1998-2008.	3.7	234
32	Activin A and Follistatin-Like 3 Determine the Susceptibility of Heart to Ischemic Injury. Circulation, 2009, 120, 1606-1615.	1.6	83
33	Genetic Analysis of the Role of Proteolysis in the Activation of Latent Myostatin. PLoS ONE, 2008, 3, e1628.	2.5	106
34	Quadrupling Muscle Mass in Mice by Targeting TGF-ÃŸ Signaling Pathways. PLoS ONE, 2007, 2, e789.	2.5	268
35	Sprinting without myostatin: a genetic determinant of athletic prowess. Trends in Genetics, 2007, 23, 475-477.	6.7	52
36	Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18117-18122.	7.1	447

#	Article	IF	Citations
37	REGULATION OF MUSCLE MASS BY MYOSTATIN. Annual Review of Cell and Developmental Biology, 2004, 20, 61-86.	9.4	706
38	Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nature, 1997, 387, 83-90.	27.8	3,596
39	Growth/Differentiation Factor-10: A New Member of the Transforming Growth Factor-Î² Superfamily Related to Bone Morphogenetic Protein-3. Growth Factors, 1995, 12, 99-109.	1.7	102
40	Limb alterations in brachypodism mice due to mutations in a new member of the TGFÎ²-superfamily. Nature, 1994, 368, 639-643.	27.8	856